CLIMB BIO, INC. Cash and Restricted Cash
CLIMB BIO, INC. (CLYM) had Cash and Restricted Cash of $44.25 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $44.25M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.36M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $35.69M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $25.80M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $44.25M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $8.36M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $35.69M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $25.80M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $22.68M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $29.02M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $87.23M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $146.18M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $223.14M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $105.03M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $93.11M 10-K · filed 2026-03-05 |
| 2023-09-30 | $57.35M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $25.29M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $34.44M 10-Q · filed 2024-05-15 |
| 2022-12-31 | $43.59M 10-K · filed 2025-03-25 |
| 2022-09-30 | $35.94M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $32.60M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $31.93M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $46.92M 10-K · filed 2024-03-28 |
| 2021-09-30 | $62.82M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $99.48M 10-Q · filed 2022-08-15 |
| 2021-03-31 | $47.91M 10-Q · filed 2022-05-16 |
| 2020-12-31 | $20.49M 10-K · filed 2023-03-06 |
| 2020-09-30 | $12.69M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $15.24M 10-Q · filed 2021-09-13 |
| 2019-12-31 | $21.22M 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |